Rapid temporal control of foxp3 protein degradation by sirtuin-1

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  van Loosdregt, Jorg ^a,b   Brunen, Diede ^a   Fleskens, Veerle ^a   Pals, Cornelieke E G M ^a   Lam, Eric W F ^c   Coffer, Paul J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; SIRT1 PROTEIN, HUMAN;

ACETYLATION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEACETYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNE RESPONSE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY T LYMPHOCYTE; TRANSCRIPTION REGULATION; UBIQUITINATION; CELL LINE; CONFOCAL MICROSCOPY; HUMAN; HYDROLYSIS; IMMUNOPRECIPITATION; KINETICS; METABOLISM; WESTERN BLOTTING;

ACETYLATION; BLOTTING, WESTERN; CELL LINE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYDROLYSIS; IMMUNOPRECIPITATION; KINETICS; MICROSCOPY, CONFOCAL; SIRTUIN 1; T-LYMPHOCYTES, REGULATORY; UBIQUITINATION;

EID: 79955438868     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019047     Document Type: Article

References (39)

1. Wang L, de Zoeten EF, Greene MI, Hancock WW, (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov 8: 969-981.
2. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW, (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138: 583-594.
3. Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, et al. (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 87: 99-104.
4. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13: 1299-1307.
5. van Loosdregt J, Vercoulen Y, Guichelaar T, Gent YY, Beekman JM, et al. (2010) Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 115: 965-974.
6. Li B, Samanta A, Song X, Iacono KT, Bembas K, et al. (2007) FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc Natl Acad Sci USA 104: 4571-4576.
7. Samanta A, Li B, Song X, Bembas K, Zhang G, et al. (2008) TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc Natl Acad Sci USA 105: 14023-14027.
8. Xiao Y, Li B, Zhou Z, Hancock WW, Zhang H, et al. (2010) Histone acetyltransferase mediated regulation of FOXP3 acetylation and Treg function. Curr Opin Immunol 22: 583-591.
9. Beier UH, Wang L, Bhatti TR, Liu Y, Han R, et al. (2011) Sirtuin-1 Targeting Promotes Foxp3+ T-Regulatory Cell Function And Prolongs Allograft Survival. Mol Cell Biol.
10. Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L, et al. (1995) The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev 9: 2888-2902.
11. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I, (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16: 4623-4635.
12. Vaziri H, Dessain SK, Ng EE, Imai SI, Frye RA, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
13. Sequeira J, Boily G, Bazinet S, Saliba S, He X, et al. (2008) sirt1-null mice develop an autoimmune-like condition. Exp Cell Res 314: 3069-3074.
14. Zhang J, Lee SM, Shannon S, Gao B, Chen W, et al. (2009) The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 119: 3048-3058.
15. Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E, (2006) Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci USA. 103: 10224-10229.
16. van Loosdregt J, van Oosterhout MF, Bruggink AH, van Wichen DF, van Kuik J, (2006) The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation 114: 1599-1607.
17. Feng L, Lin T, Uranishi H, Gu W, Xu Y, (2005) Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 25: 5389-5395.
18. Gronroos E, Hellman U, Heldin CH, Ericsson J, (2002) Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 10: 483-493.
19. Zhao Y, Lu S, Wu L, Chai G, Wang H, et al. (2006) Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26: 2782-2790.
20. Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, et al. (2007) SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 21: 2644-2658.
21. Zhang HS, Sang WW, Wang YO, Liu W, (2010) Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation. J Cell Biochem 110: 1464-1470.
22. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, et al. (2007) Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445: 931-935.
23. Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, et al. (2005) The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 115: 3276-3284.
24. Fontenot JD, Gavin MA, Rudensky AY, (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336.
25. Khattri R, Cox T, Yasayko SA, Ramsdell F, (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4: 337-342.
26. Williams LM, Rudensky AY, (2007) Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 8: 277-284.
27. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, et al. (2006) Single-cell analysis of normal and FOXP3-mutant human T cells:FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 103: 6659-6664.
28. Wang J, Ioan-Facsinay A, van d V, Huizinga TW, Toes RE, (2007) Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 37: 129-138.
29. Akimova T, Ge G, Golovina T, Mikheeva T, Wang L, et al. (2010) Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 136: 348-363.
30. Greenbaum CJ, Kahn SE, Palmer JP, (1996) Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes 45: 1631-1634.
31. Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, et al. (1998) The Deutsche Nicotinamide Intervention Study:an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 47: 980-984.
32. Hoffer A, Callbeack MJ, (1959) Effect of nicotinic acid on liver function and leukocytes. Can Med Assoc J 80: 736-737.
33. Jonas WB, Rapoza CP, Blair WF, (1996) The effect of niacinamide on osteoarthritis:a pilot study. Inflamm Res 45: 330-334.
34. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, et al. (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199: 1455-1465.
35. Morgan ME, Sutmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, et al. (2003) CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 48: 1452-1460.
36. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, et al. (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200: 277-285.
37. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, et al. (2005) Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54: 92-99.
38. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, et al. (2007) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19: 345-354.
39. Allan SE, Alstad AN, Merindol N, Crellin NK, Amendola M, et al. (2008) Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol Ther 16: 194-202.